<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992067</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCH-CK19A</org_study_id>
    <nct_id>NCT02992067</nct_id>
  </id_info>
  <brief_title>CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer</brief_title>
  <acronym>CK-CEUS</acronym>
  <official_title>CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish a predicting system on axillary lymph node metastasis based on peripheral blood
      CK19mRNA and contrast-enhanced ultrasound.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The feasibility and predictive accuracy of peripheral blood CK19mRNA and contrast-enhanced
      ultrasound of axillary lymph nodes metastasis in breast cancer were verified by the data of
      specimen bank; to establish the evaluation system of predicting the lymph node status based
      on CK19 and CEUS, validate the sensitivity, specificity, negative predictive value, positive
      predictive value and ROC curve of the system model and use Youden index, negative likelihood
      ratio, positive likelihood ratio to evaluate the diagnostic efficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The accuracy of CK19 combined with CEUS predicting value on involved lymph node</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">389</enrollment>
  <condition>Lymph Node</condition>
  <condition>Breastcancer</condition>
  <arm_group>
    <arm_group_label>Operable breast cancer</arm_group_label>
    <description>clinical stage: cTis, cI, cII, cT3N1M0</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Operable breast cancer patients (clinical stage: cTis, cI, cII, cT3N1M0)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female, age 18~70 years old

          2. the test group should be in accordance with the pathological diagnosis of breast
             cancer, the clinical stage of breast cancer (stage cTis, cI, cII and cT3N1M0), the
             initial treatment to receive surgical treatment. Complete preoperative clinical
             diagnosis data, including the ipsilateral axillary lymph node CEUS data and peripheral
             blood sample; The negative-control group should comply with the pathological
             diagnosis, breast adenosis, fibrocystic lesions, breast cysts and other benign
             lesions, with complete preoperative clinical data, also including ipsilateral axillary
             lymph node CEUS data and peripheral blood sample

        Exclusion criteria:

          1. metastatic breast cancer, inflammatory breast disease, surgery without lymph node
             staging

          2. pregnancy or lactation

          3. patients with hematopoietic system disease or cancer, autoimmune diseases

          4. preservation of substandard peripheral blood samples.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingfei Yu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>YU Xingfei</investigator_full_name>
    <investigator_title>Breast Tumor Surgery (Department 104)</investigator_title>
  </responsible_party>
  <keyword>lymph node metastasis</keyword>
  <keyword>breast cancer</keyword>
  <keyword>CK19</keyword>
  <keyword>contrast-enhanced ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

